OneLavi.com Will Soon Offer Enzolytics IPF Immune™

OneLavi.com, a health and wellness e-commerce site, will soon carry Enzolytics IPF Immune™, a new immune modulator from a Texas biotech company.

“We are excited to receive confirmation that OneLavi.com’s consumers will soon be able to buy our immune modulator dietary supplement, Enzolytics IPF Immune™,” said Charles S. Cotropia, CEO of Enzolytics, Inc. “We develop therapeutics to treat numerous human health conditions. Enzolytics IPF Immune™ is our first over-the-counter product, which is for people who want to boost their body’s defenses against illnesses.”

Enzolytics IPF Immune™ is a liquid nutritional supplement that acts as an immune modulator to benefit the immune system by fortifying it against infections.

“Our immune modulator, which has been registered with the FDA for use in the United States, can be taken by itself or as part of a therapy for a variety of ailments,” said Harry Zhabilov, the company’s Chief Scientific Officer. “We encourage patients who have completed chemotherapy to consider Enzolytics IPF Immune™ because it can speed recovery from after-treatment side effects.”

Although OneLavi.com will be one of the first retailers to offer Enzolytics IPF Immune™, Mr. Cotropia said the company presented IPF Immune™ last month to retail buyers who participated in ECRM’s “Weight Management, Nutrition, and Vitamin Program.”

ECRM brings buyers and brands with new products together for private one-on-one meetings. Buyers attending the ECRM event represented regional and national food, drug and mass health chains.

“We have a product that we believe consumers want,” he added. “Although the company’s research and development of the immune modulator began before COVID-19, the pandemic has forced people to concentrate on their overall health.

“As a result of the past two years, consumers have increased their spending on immune defense supplements,” Mr. Cotropia added.

Enzolytics IPF Immune™ is a nutritional supplement that is taken orally two consecutive days per week for eight consecutive weeks.

For more information, email [email protected] or visit enzolytics.com.

Disclaimer: The statements made regarding these products have not been evaluated by the Food and Drug Administration. This press release is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please check with your doctor. The news site hosting this press release is not associated with Enzolytics, Inc. It is merely publishing a press release announcement submitted by a company, without any stated or implied endorsement of the product or service.

Company Contact:
Enzolytics, Inc.
2000 North Central Expressway
Plano, TX 75074

Research Center
Enzolytics, Inc.
Texas A&M University
Institute for Preclinical Studies
College Station, TX 77843-44
SOURCE: Enzolytics, Inc.

About Enzolytics, Inc.

Enzolytics Inc. is a Texas-based biotechnology company that focuses on therapeutics to treat numerous human health medical conditions. In addition to Enzolytics IPF Immune™, which will be on the U.S. market soon, the Company is developing other therapeutics for treating multiple infectious diseases, including monoclonal antibodies for treating COVID-19 and HIV, and anti-cancer therapeutics.

Press Contact

Name: Robert Grant Phone: 5615440719 Email: Contact Us Website: https://inhealthmedia.com/